Citations

Clear

1794 citation(s) found for "Yu, Stephanie".

Tumor markers of efficacy and resistance to cetuximab (C) treatment in metastatic colorectal cancer (mCRC): Results from CALGB 80203 (Alliance).
Hurwitz, Herbert I. , Cushman, Stephanie M., Jiang, Chen , Shterev, Ivo , Mahoney, Michelle R., Niedzwiecki, Donna , Mayer, Robert J. , Venook, Alan P. , Owzar, Kouros , Nixon, Andrew B.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 31 | Issue: 15_suppl | Pages: 11011-11011

10.1200/jco.2013.31.15_suppl.11011 Get It

11011 Background: Beyond KRAS status, there are no validated markers for anti-EGFR therapy in mCRC. While expression of genes within the EGF signaling axis has been reported to correlate with benefit, most reports used data from non-randomized trials which cannot distinguish between general prognostic markers and markers that predict for benefit from C. CALGB 80203 was a 238-patient (pt), 4-arm, randomized phase II study of FOLFOX or FOLFIRI +/- C in mCRC pts. Formalin-fixed, paraffin-embedded (FFPE) tumor samples from CALGB 80203 were analyzed for gene expression of HER family ligands, receptors and regulators. Methods: FFPE tumor samples from consenting pts were analyzed for AREG, BTC, CD73, DUSP4, EGF, EGFR, EPGN, EREG, HB-EGF, HER2, HER3, HER4, PHLDA1 and TGFa by RT-qPCR. Interaction between baseline gene expression levels and treatment (C) with respect to progression-free survival (PFS) and overall survival (OS) was modeled using a multiplicative Cox proportional hazards model. Results: Baseline tumor tissue was available from 103 pts; 55% of tumors were KRAS wild type (WT). Two prognostic markers were identified; higher tumor mRNA levels of HER2 (HR=0.64, p=0.002) and EREG (HR=0.89, p=0.016) were associated with longer PFS across all pts. Potential predictive markers of benefit for C were identified. In KRAS WT tumors, lower HER3 expression was associated with longer OS from C treatment while higher HER3 expression was associated with shorter OS from C treatment (chemo + C: HR=1.15; chemo only: HR=0.48, interaction p=0.029). No association was observed for HER3 and outcome in KRAS mutant (MT) tumors. Interestingly, higher CD73 expression was associated with longer PFS in C-treated pts in both KRASWT (chemo + C: HR=0.91; chemo only: HR=1.57, interaction p=0.026) and MT tumors (chemo + C: HR=0.80; chemo only: HR=1.29, p=0.025). Conclusions: In one of the first reports using data from a randomized study, gene expression of HER3 and CD73 were identified as potential predictive markers for C. These data implicate not only HER axis signaling but also immune modulation as potential mechanisms of C action and sensitivity, and warrant confirmation in other large randomized trials.
Preliminary results of RTOG 0831, a randomized, double-blinded, placebo-controlled trial of tadalafil in the prevention of erectile dysfunction in patients treated with radiotherapy for prostate cancer.
Pugh, Stephanie L. , Pisansky, Thomas M. , Greenberg, Richard E. , Pervez, Nadeem , Mowat, Rex B., Raben, Adam , Buyyounouski, Mark K. , Kachnic, Lisa A. , Bruner, Deborah Watkins , Reed, Daniel R. , Rosenthal, Seth A.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 31 | Issue: 15_suppl | Pages: 9525-9525

10.1200/jco.2013.31.15_suppl.9525 Get It

9525 Background: Determine if prophylactic tadalafil maintains spontaneous (off-drug) erectile function (EF) compared to placebo in patients (pts) treated with radiotherapy (RT) for prostate cancer. Methods: Double-blind 1:1 randomization to tadalafil 5mg daily for 6 mos vs placebo starting with RT. Primary outcomes measured by International Index of Erectile Function (IIEF). Eligibility included pre-RT IIEF Question [Q] 1 response “sometimes/most times/always” able to get an erection. Ps treated with hormones were excluded. Primary outcome was response to IIEF Q1 at 30 wks (6 wks off drug). Pts were stratified by RT modality (external vs. brachytherapy) and age (≤65 vs. >65 years). 182 pts were needed in an intent-to-treat analysis to show a difference from 20% responders with placebo to 40% with tadalafil based on a 2-sided Fishers exact test with α=0.05 and 80% power. Results: We report on 155/222 analyzable/eligible pts. Median age was 63 years, white (73%), and external RT (63%). Mean total dose for external RT was 77.23 Gy and 136.74 Gy for brachytherapy with penile bulb D50 of 24.46 Gy and 31.24 Gy respectively. Most pts completed treatment per protocol (84% tadalafil, 70% placebo). Spontaneous EF at 30 wks from drug start was not different (p=0.99) between arms based on IIEF Q1 response, total IIEF score (52.5 drug vs 52.8 placebo), or score change from baseline (-8.0 drug vs -8.8 placebo). No difference in these outcomes was noted at 1 year. Non-responders at 30 wks were likely to be older (age≥65; p=0.432), but there were no significant predictors at 1 year. About 80% of pts maintained spontaneous EF in both arms. Conclusions: Low-dose daily tadalafil did not preserve EF within the first year of RT for prostate cancer. If tadalafil positively influences delayed RT-induced vasogenic injury, additional time may be needed to observe a benefit to tadalafil as a preventive agent. Alternatively, tadalafil dose modification or altered dosing schedules may be needed to demonstrate a protective effect of this agent when used with RT. Clinical trial information: NCT00951184.
Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimens.
Khera, Nandita , Emmert, Amy, Storer, Barry E. , Alyea, Edwin P. , Sandmaier, Brenda M , Lee, Stephanie J.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 31 | Issue: 15_suppl | Pages: 7034-7034

10.1200/jco.2013.31.15_suppl.7034 Get It

7034 Background: Reduced intensity (RIC) conditioning regimens have allowed older patients and those with comorbidities to receive hematopoietic cell transplantation (HCT). Methods: We analyzed medical costs from the beginning of conditioning to 100 days after HCT for 484 patients who underwent a RIC allogeneic HCT at Fred Hutchinson Cancer Research Center (FHCRC; n=147) and Dana Farber Cancer Institute (DFCI; n=337) from 1/2008 to 12/2010. Costs up to 2 years after HCT were analyzed for DFCI (n=311) as most patients receive their post-transplant care there. Multiple linear regression was used to analyze the association between clinical variables and costs. Results: Disease distribution and transplant characteristics were comparable between the two sites, though significant differences were seen in age distribution (88% FHCRC patients ≥ 50 years vs. 80% at DFCI, p=0.04) and pre-transplant performance scores (63% patients with Karnofsky score≥ 90 at FHCRC vs. 47% at DFCI; p=0.006). Median costs for first 100 days in 2010 $ at FHCRC and DFCI were $129 000 (range 31,000-352,000) and $96,000 (3,000-614,000) respectively, p=0.0002, but differences were not significant in multivariate analysis. Inpatient costs accounted for 42% of early costs at FHCRC and 87% at DFCI.Significant predictors for early costs included a diagnosis of lymphoma/ myeloma (17% decrease in costs; p=0.01), donors other than matched related (50 -100% increase; p<0.001), relapse (17% increase, p=0.04) and ≥ grade II acute GVHD (37% increase; p<0.001). Median costs between d100 and 2 years were $39,000 (0-976,000) at DFCI. 39% of the 2 year costs occurred after first 100 days. There was no association of late costs with pre-transplant variables, and only death was associated with higher costs (138% increase; p=0.005). Conclusions: After adjustment for pre and post HCT variables, the overall costs of the RIC allogeneic transplants were similar between the two institutions despite different management approaches (inpatient vs. outpatient conditioning) and accounting methodologies. Use of unrelated/ alternative donors, relapse and acute GVHD were predictors for higher early costs while only death was associated with higher late costs.
Validation of a genomic-clinical classifier for predicting clinical progression in high-risk prostate cancer.
Buerki, Christine, Mitra, Anirban P. , Ghadessi, Mercedeh , Bergstralh, Eric J., Erho, Nicholas , Carlson, R. W. , Crisan, Anamaria, Sierocinski, Thomas , Zimmermann, Benedikt, Haddad, Zaid , Klee, George G., Fink, Stephanie, Karnes, R. Jeffrey , Jenkins, Robert B. , Black, Peter C. , Vergara, Ismael A. , Ballman, Karla V. , Kollmeyer, Thomas M. , Triche, Timothy J. , Davicioni, Elai

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 30 | Issue: 15_suppl | Pages: 4565-4565

10.1200/jco.2012.30.15_suppl.4565 Get It

4565 Background: The efficient delivery of adjuvant therapy after radical prostatectomy (RP) in patients with prostate cancer is limited by the lack of biomarkers, beyond clinicopathologic factors, that are able to assess the risk of clinically significant disease progression. Previously, routine FFPE patient specimens from the Mayo Clinic Radical Prostatectomy Registry with long term follow-up were selected to develop a genomic classifier (GC) to predict clinical progression. Here, we present the validation of a GC in a cohort of patients at high risk of disease progression. Methods: A case-cohort study of high-risk RP patients from the Mayo Clinic (N=219) was used to validate the genomic classifier (GC) for predicting clinical progression (defined by positive bone or CT scan post-RP). Its performance was compared to a multivariable clinical classifier (CC) and a genomic-clinical classifier (GCC) which combines GC with established clinicopathologic variables. Concordance index, Cox modeling and decision curve analysis were used to compare the different models. Results: GC and GCC were predictive of clinical progression in the high-risk cohort with c-indices of 0.79 and 0.82, respectively, compared to the clinical classifier (0.70). Multivariable survival analysis showed that the majority of prognostic information of GCC came from the GC with a minor contribution from Gleason score. Decision curve analysis showed that GCC had a higher overall net benefit compared to CC over a wide range of ‘decision-to-treat’ thresholds for the risk of progression. Conclusions: In this high-risk cohort, GC and GCC classifiers showed improved performance over CC in prediction of clinical progression. GC is an independent prognostic factor in this cohort and captures the majority of prognostic information. GC and GCC’s prognostic performance and their usefulness in guiding decision-making in the adjuvant setting after RP need further testing in studies of additional prostate cancer risk groups.
Factors associated with syrinx size in pediatric patients treated for Chiari malformation type I and syringomyelia: a study from the Park-Reeves Syringomyelia Research Consortium
Hale, Andrew T. , Adelson, P. David , Albert, Gregory W. , Aldana, Philipp R. , Alden, Tord D. , Anderson, Richard C. E. , Bauer, David F. , Bonfield, Christopher M. , Brockmeyer, Douglas L. , Chern, Joshua J. , Couture, Daniel E., Durham, Susan, Ellenbogen, Richard G. , Eskandari, Ramin , George, Timothy M., Greene, Stephanie , Gross, Naina L. , Guillaume, Daniel, Heuer, Gregory G. , Iantosca, Mark, Iskandar, Bermans J. , Jackson, Eric M. , Johnston, James M. , Keating, Robert F., Leonard, Jeffrey R. , Maher, Cormac O. , Mangano, Francesco T. , McComb, J. Gordon , Meehan, Thanda, O’Neill, Brent R., Olavarria, Greg, Ragheb, John , Smyth, Matthew D. , Stone, Scellig , Strahle, Jennifer M. , Wait, Scott D. , Wellons, John C. , Whitehead, William E. , Shannon, Chevis N. , Limbrick, David D. , _, _, Daniels, David J. , Grant, Gerald A. , Graupman, Patrick C. , Greenfield, Jeffrey P. , Guillaume, Daniel J., Menezes, Arnold H. , Park, Tae Sung , Selden, Nathan R. W. , Shah, Manish N. , Limbrick, David D. , _, _, Hale, Andrew T

Mayo Clinic

Journal of Neurosurgery: Pediatrics | March 6, 2020 | Volume: 25 | Issue: 6 | Pages: 629-639

10.3171/2020.1.peds19493 | PMID 32114543 Get It

OBJECTIVEFactors associated with syrinx size in pediatric patients undergoing posterior fossa decompression (PFD) or PFD with duraplasty (PFDD) for Chiari malformation type I (CM-I) with syringomyelia (SM; CM-I+SM) are not well established.METHODSUsing the Park-Reeves Syringomyelia Research Consortium registry, the authors analyzed variables associated with syrinx radiological outcomes in patients (< 20 years old at the time of surgery) with CM-I+SM undergoing PFD or PFDD. Syrinx resolution was defined as an anteroposterior (AP) diameter of ≤ 2 mm or ≤ 3 mm or a reduction in AP diameter of ≥ 50%. Syrinx regression or progression was defined using 1) change in syrinx AP diameter (≥ 1 mm), or 2) change in syrinx length (craniocaudal, ≥ 1 vertebral level). Syrinx stability was defined as a < 1-mm change in syrinx AP diameter and no change in syrinx length.RESULTSThe authors identified 380 patients with CM-I+SM who underwent PFD or PFDD. Cox proportional hazards modeling revealed younger age at surgery and PFDD as being independently associated with syrinx resolution, defined as a ≤ 2-mm or ≤ 3-mm AP diameter or ≥ 50% reduction in AP diameter. Radiological syrinx resolution was associated with improvement in headache (p < 0.005) and neck pain (p < 0.011) after PFD or PFDD. Next, PFDD (p = 0.005), scoliosis (p = 0.007), and syrinx location across multiple spinal segments (p = 0.001) were associated with syrinx diameter regression, whereas increased preoperative frontal-occipital horn ratio (FOHR; p = 0.007) and syrinx location spanning multiple spinal segments (p = 0.04) were associated with syrinx length regression. Scoliosis (HR 0.38 [95% CI 0.16–0.91], p = 0.03) and smaller syrinx diameter (5.82 ± 3.38 vs 7.86 ± 3.05 mm; HR 0.60 [95% CI 0.34–1.03], p = 0.002) were associated with syrinx diameter stability, whereas shorter preoperative syrinx length (5.75 ± 4.01 vs 9.65 ± 4.31 levels; HR 0.21 [95% CI 0.12–0.38], p = 0.0001) and smaller pB-C2 distance (6.86 ± 1.27 vs 7.18 ± 1.38 mm; HR 1.44 [95% CI 1.02–2.05], p = 0.04) were associated with syrinx length stability. Finally, younger age at surgery (8.19 ± 5.02 vs 10.29 ± 4.25 years; HR 1.89 [95% CI 1.31–3.04], p = 0.01) was associated with syrinx diameter progression, whereas increased postoperative syrinx diameter (6.73 ± 3.64 vs 3.97 ± 3.07 mm; HR 3.10 [95% CI 1.67–5.76], p = 0.003), was associated with syrinx length progression. PFD versus PFDD was not associated with syrinx progression or reoperation rate.CONCLUSIONSThese data suggest that PFDD and age are independently associated with radiological syrinx improvement, although forthcoming results from the PFDD versus PFD randomized controlled trial (NCT02669836, clinicaltrials.gov) will best answer this question.
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Andrews, Stephanie, Armand, Philippe , Davies, Marianne, Dunnington, David, Frigault, Matthew J. , Kaffenberger, Benjamin H. , Lunning, Matthew A. , McGettigan, Suzanne , McPherson, Jordan P. , Mohindra, Nisha , Naidoo, Jarushka , Olszanski, Anthony J. , Oluwole, Olalekan O. , Patel, Sandip Pravin , Reddy, Sunil , Ryder, Mabel , Santomasso, Bianca , Shofer, Scott , Sosman, Jeffrey A. , Weight, Ryan , Johnson-Chilla, Alyse, Zuccarino-Catania, Griselda, Engh, Anita M. , Oluwole, Olalekan O , Naidoo, Jarushka , Olszanski, Anthony J , Kaffenberger, B , Ryder, Mabel , Bhatia, Shailender , Budde, Lihua E. , Costa, Luciano J. , Ernstoff, Marc S. , Pennell, Nathan A , Wang, Yinghong

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 5, 2020 | Volume: 18 | Issue: 3 | Pages: 230-241

10.6004/jnccn.2020.0012 | PMID 32135517 Get It

The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor–related diarrhea/colitis and cardiovascular irAEs.
Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor–Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance)
Hwang, E. Shelley , Hyslop, Terry , Hendrix, Laura H., Duong, Stephanie Q. , Price, Elissa R. , Caudle, Abigail S. , Guenther, Joseph M., Hudis, Clifford A. , Lyss, Alan P., Dickson-Witmer, Diana , Ollila, David W. , Hardman, Timothy, Marks, Jeffrey R. , Chen, Yunn-Yi, Krings, Gregor , Esserman, Laura J. , Duong, Stephanie, Hieken, Tina, Esserman, Laura J , Bedrosian, Isabelle , Hieken, Tina J. , Winer, Eric P. , Hoefer, Richard, Chen, Yunn‐Yi , Hylton, Nola M.

Mayo Clinic

Journal of Clinical Oncology | March 3, 2020 | Volume: 38 | Issue: 12 | Pages: 1284-1292

10.1200/jco.19.00510 | PMID 32125937 Get It

PURPOSE Primary endocrine therapy for ductal carcinoma in situ (DCIS) as a potential alternative to surgery has been understudied. This trial explored the feasibility of a short-term course of letrozole and sought to determine whether treatment results in measurable radiographic and biologic changes in estrogen receptor (ER)–positive DCIS. PATIENTS AND METHODS A phase II single-arm multicenter cooperative-group trial was conducted in postmenopausal patients diagnosed with ER-positive DCIS without invasion. Patients were treated with letrozole 2.5 mg per day for 6 months before surgery. Breast magnetic resonance imaging (MRI) was obtained at baseline, 3 months, and 6 months. The primary end point was change in 6-month MRI enhancement volume compared with baseline. RESULTS Overall, 79 patients were enrolled and 70 completed 6 months of letrozole. Of these, 67 patients had MRI data available for each timepoint. Baseline MRI volumes ranged from 0.004 to 26.3 cm 3 . Median reductions from baseline MRI volume (1.4 cm 3 ) were 0.6 cm 3 (61.0%) at 3 months ( P < .001) and 0.8 cm 3 (71.7%) at 6 months ( P < .001). Consistent reductions were seen in median baseline ER H-score (228; median reduction, 15.0; P = .005), progesterone receptor H-score (15; median reduction, 85.0; P < .001), and Ki67 score (12%; median reduction, 6.3%; P = .007). Of the 59 patients who underwent surgery per study protocol, persistent DCIS remained in 50 patients (85%), invasive cancer was detected in six patients (10%), and no residual DCIS or invasive cancer was seen in nine patients (15%). CONCLUSIONS In a cohort of postmenopausal women with ER-positive DCIS, preoperative letrozole resulted in significant imaging and biomarker changes. These findings support future trials of extended endocrine therapy as primary nonoperative treatment of some DCIS.
The Prevalence of Expiratory Flow Limitation in Youth Elite Male Cyclists
COX, KATHERINE R., Smith, Joshua R. , Luden, Nicholas D. , Saunders, Michael, Smith, Joshua R , Kurti, Stephanie P.

Mayo Clinic

Medicine & Science in Sports & Exercise | February 26, 2020 | Volume: 52 | Issue: 9 | Pages: 1933-1939

10.1249/mss.0000000000002325 | PMID 32102060 Get It

ABSTRACT The present investigation tested the hypotheses that there would be greater prevalence of expiratory flow limitation (EFL) in endurance-trained (ET) youth cyclists compared with a recreationally active control (CON) group. METHODS Twelve ET youth male cyclists (16.3 ± 1.0 yr (13–18 yr), 176.5 ± 6.2 cm, 64.2 ± 5.9 kg) and 12 CON subjects (17.6 ± 2.2 yr (13–18 yr), 177.9 ± 7.1 cm, 74.8 ± 11.2 kg) completed an incremental exercise test to determine peak oxygen consumption (V˙O 2peak ) on a cycle ergometer. Maximal flow volume loops (MFVL), forced vital capacity (FVC), forced expiratory volume in 1 s (FEV 1 ), FEV 1 /FVC, forced expiratory flow between 25% and 75% of FVC, and peak expiratory flow were assessed before and after exercise, with inspiratory capacity maneuvers and dyspnea ratings measured in the last 20 s of each stage. EFL was quantified as the percentage of the expiratory tidal volume that overlapped with the maximal flow volume loop. RESULTS V˙O 2peak , dyspnea ratings at peak, and ventilation were higher in the ET compared with CON group ( P < 0.05). The ET group experienced greater EFL prevalence at V˙O 2peak , with 11 of 12 subjects exhibiting EFL compared with 5 of 12 subjects in the CON group ( P = 0.014). When matched for absolute ventilation of 20, 40, 60, 80, and 100 L·min −1 , there were no differences in EFL severity between the ET and CON groups ( P = 0.473). CONCLUSIONS Elite youth male cyclists have a greater prevalence of EFL at maximal exercise than do CON subjects who are similar in age, height, and lung size. Future research should determine whether EFL in youth ET male cyclists may limit their exercise performance.
Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α
Ingle, James N. , Cairns, Junmei , Shepherd, Lois E. , Fasching, Peter A. , Desta, Zeruesenay , Ellis, Matthew J. , Goss, Paul E. , Volz, Bernhard , Barman, Poulami , Haddad, Tufia C. , Goodnature, Barbara, Cuellar, Matthew E. , Correia, Cristina , Weinshilboum, Richard M. , Wang, Liewei , Fasching, Peter A , Hoskin, Tanya L. , Ellis, Matthew J , Haddad, Tufia, Cuellar, Matthew E , Correia, Cristina , Kaufmann, Scott H , Ingle, J , Suman, Vera J. , Singh, Ravinder J. , Kalari, Krishna R. , Chen, Bingshu E. , Carlson, Erin E. , Goetz, Matthew P. , Walters, Michael A. , Kaufmann, Scott H. , Weinshilboum, Richard M.

Mayo Clinic

Clinical Cancer Research | February 25, 2020 | Volume: 26 | Issue: 12 | Pages: 2986-2996

10.1158/1078-0432.ccr-19-3091 | PMID 32098767 Get It

Abstract Purpose: To determine if the degree of estrogen suppression with aromatase inhibitors (AI: anastrozole, exemestane, letrozole) is associated with efficacy in early-stage breast cancer, and to examine for differences in the mechanism of action between the three AIs. Experimental Design: Matched case–control studies [247 matched sets from MA.27 (anastrozole vs. exemestane) and PreFace (letrozole) trials] were undertaken to assess whether estrone (E1) or estradiol (E2) concentrations after 6 months of adjuvant therapy were associated with risk of an early breast cancer event (EBCE). Preclinical laboratory studies included luciferase activity, cell proliferation, radio-labeled ligand estrogen receptor binding, surface plasmon resonance ligand receptor binding, and nuclear magnetic resonance assays. Results: Women with E1 ≥1.3 pg/mL and E2 ≥0.5 pg/mL after 6 months of AI treatment had a 2.2-fold increase in risk (P = 0.0005) of an EBCE, and in the anastrozole subgroup, the increase in risk of an EBCE was 3.0-fold (P = 0.001). Preclinical laboratory studies examined mechanisms of action in addition to aromatase inhibition and showed that only anastrozole could directly bind to estrogen receptor α (ERα), activate estrogen response element-dependent transcription, and stimulate growth of an aromatase-deficient CYP19A1−/− T47D breast cancer cell line. Conclusions: This matched case–control clinical study revealed that levels of estrone and estradiol above identified thresholds after 6 months of adjuvant anastrozole treatment were associated with increased risk of an EBCE. Preclinical laboratory studies revealed that anastrozole, but not exemestane or letrozole, is a ligand for ERα. These findings represent potential steps towards individualized anastrozole therapy.
The Lyme Disease Biobank: Characterization of 550 Patient and Control Samples from the East Coast and Upper Midwest of the United States
Horn, Elizabeth J. , Dempsey, George, Schotthoefer, Anna M. , Prisco, U. Lena, McArdle, Matthew, Gervasi, Stephanie S. , Golightly, Marc G., Luca, Cathy De, Evans, M. B., Pritt, Bobbi S. , Theel, Elitza S. , Iyer, Radha, Liveris, Dionysios , Wang, Guiqing , Goldstein, Don, Schwartz, Ira , Pritt, Bobbi S , Horn, Elizabeth J , Dempsey, George

Mayo Clinic

Journal of Clinical Microbiology | February 24, 2020 | Volume: 58 | Issue: 6 | Pages: No page available

10.1128/jcm.00032-20 | PMID 32102853 Get It

Lyme disease (LD) is an increasing public health problem. Current laboratory testing is insensitive in early infection, the stage at which appropriate treatment is most effective in preventing disease sequelae. The Lyme Disease Biobank (LDB) collects samples from individuals with symptoms consistent with early LD presenting with or without erythema migrans (EM) or an annular, expanding skin lesion and uninfected individuals from areas of endemicity. Samples were collected from 550 participants (298 cases and 252 controls) according to institutional review board-approved protocols and shipped to a centralized biorepository.